Watch for Injectable Semaglutide to Treat Fatty Liver

April 2026

Injectable semaglutide (Wegovy) is the first GLP-1 agonist approved for metabolic dysfunction-associated steatohepatitis (MASH) treatment.

MASH is when fat builds up in the liver...leading to inflammation and liver damage. If left untreated, it can progress to fibrosis (or scarring), cirrhosis (severe scarring), liver failure, or even death.

It’s closely linked with cardiometabolic risk factors, such as obesity, diabetes, hypertension, and high cholesterol.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote